News bei Nanotech-Aktie Acacia Research Combimatrix (WKN 164630) - 500 Beiträge pro Seite

[Dirac]

Combimatrix entwickelt Chips, mit deren Hilfe unter anderem Viruserkrankungen, wie z.B. SARS, HIV, Herpes, Hepatitis, Influenza usw. schnell diagnostiziert und behandelt werden können.
Dies bietet sicherlich ein großes Anwendungsfeld.

Der Hauck und Aufhäuser Lux DAC Nanotech Fond nennt in seiner Liste der 10 Nano-Tech Favoriten von Ende Oktober2003 auch die Acacia Research CombiMatrix.

Ein großer Nachteil scheint mir aber zu sein, dass in Deutschland die Aktie sehr wenig Umsatzvolumen hat.
Wenn man sich zu einem Einstieg entschließt, sollte man vielleicht direkt an der Nasdaq ordern (Kürzel CBMX).

PS. Die Aktie ist auf Grund der obigen Pressemiteilungen unter großem Umsatz um ca. 5% gestiegen.

Ich denke, das ist eine Aktie für die Watchlist.

[Dirac]

Hier die Nachricht:

Das Unternehmen gibt eine Kooperation mit der Washington-University bekannt:


Press Release Source: Acacia Research Corporation

CombiMatrix and Washington University in St. Louis Collaborate on Nanoscale Synthesis of Chemical Libraries
Tuesday January 20, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jan. 20, 2004--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix Group and Washington University in St. Louis are collaborating to develop a system for the synthesis of libraries of diverse, non-nucleic acid molecules. These libraries will be synthesized using CombiMatrix`s semiconductor based microarrays and electrochemical synthetic methods. CombiMatrix NanoArrays(TM) will be used for the diverse chemical synthesis.

The research at Washington University in St. Louis is being funded by a grant from the National Science Foundation. Professor Kevin D. Moeller, Principle Scientist on the NSF grant, is exploring the capabilities of the CombiMatrix technology platform for building spatially addressed diverse molecular libraries on a chip.

CombiMatrix`s NanoArrays(TM) incorporate thousands of independently addressable micro-electrodes on a semiconductor chip. This array technology has been used for applications in genetic analysis, RNAi drug discovery, biodefense applications, chemical sensing, and nanomaterials discovery. This collaboration seeks to expand the applicability of this technology for the synthesis of diverse molecular libraries.

Professor Moeller commented, " While the technological advantages of CombiMatrix`s semiconductor based microarrays are obvious, this research will define the full range of synthetic chemistry that can be accomplished on an electrochemically addressable chip thereby allowing us to take full advantage of chip-based molecular screening methods in the future."

" This is yet an additional application of our arrays in the nanotechnology field," said Dr. Amit Kumar, President and Chief Executive Officer of CombiMatrix. " We have internally demonstrated synthesis of numerous nucleic acids, peptides and other non-biological chemicals on our arrays, and this collaboration will expand that work to include additional chemicals by adapting both well known and entirely new chemical reactions for use on CombiMatrix`s unique chip platform. The funding provided by the NSF provides validation for this work."



ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix`s technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand.
CombiMatrix`s Express Track(SM) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. The initial focus of Express Track(SM) includes the following viral diseases:

Virus Collaborator

SARS NIAID/USAMRIID

HIV type 1 irsiCaixa-Dr. Bonaventura Clotet

HIV type 2 To Be Announced

West Nile virus To Be Announced

Human Papillomavirus type 16 To Be Announced

Human Herpes 8 (Kaposi`s sarcoma) To Be Announced

Smallpox (Variola) To Be Announced

Influenza virus A To Be Announced

Influenza virus B To Be Announced

Hepatitis C To Be Announced

CombiMatrix is also establishing applications of its arrays
through other partnerships as follows:

Project Collaborator

Cancer Diagnosis (Lymphoma) University of Washington/Rational
Diagnostics

RNA Drug Targets Professor Gregory L. Verdine,
Harvard University

Parasite

Leishmania Seattle Biomedical Research Institute

Trypasonoma Seattle Biomedical Research Institute

The Acacia Technologies group licenses its Digital Media Transmission (DMT) technology to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 31 foreign patents.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the " safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[Dirac]

Ich suche noch andere User, die eventuell Genaueres über den Stand der Forschung bei Combimatrix liefern können.

Bin um jeden Beitrag dankbar, da ich ernsthaft einen Einstieg erwäge.

Grüße Dirac

[Sylow]

Du hast recht,Dirac
Combimatrix ist ein interessantes Unternehmen.

Hier noch eine Nachricht von letzter Woche:

Das Unternehmen COMBIMATRIX wird mit CYRANO SCIENCES zusammenarbeiten.
Beide Unternehmen bringen ihre jeweiligen Technologie-Fähigkeiten ein - COMBIMATRIX seine Erfahrungen mit Mikroarrays und CYRANO sein Know-how bei elektronischer Geruchstechnologie - und entwickeln gemeinsam chemische Sensoren.
Zeit: 15.01.2004.
Quelle: Electronic News vom 12.01.2004.

Gruß
Sylow

[Dirac]

Hier noch ein Bericht über CombiMatrix aus der neuesten Ausgabe von BusinessWeek-online vom 26.01.2004



INSIDE WALL STREET
By Gene G. Marcial


Why CombiMatrix Is Going Gaga Over Nano

Nanotech is the Street`s latest buzzword. Technology Review, put out by Massachusetts Institute of Technology, calls it the key materials technology for this century, capable of altering the performance of drugs, chemicals, and computers. So investors are chasing nano stocks. Enter CombiMatrix (CBMX ) (CBMX), whose stock climbed from 3 in mid-December to 5.39 on Jan. 14.

First featured in this column on Feb. 3, 2003, at 2.90, CombiMatrix makes micro-biochips that perform DNA diagnostics and detect hazardous chemicals. In December, the U.S. Army inked a pact with CombiMatrix to develop microchips for detecting hazardous biotech agents. CombiMatrix` partner, Nanomaterials Discovery, has just agreed to use CombiMatrix` biochips to develop fuel cells, rechargeable lithium batteries, and phosphors for flat-panel displays.

Jonathan Aschoff of Brean Murray says Nanomaterials Discovery has a patent on using its own technology and CombiMatrix` biochips to discover new nanomaterials. Aschoff, who rates CombiMatrix a strong buy , says its microchips shorten the discovery process. Aschoff has a 12-month target of 8, expects the company to turn profitable this year, with earnings of 45 cents a share


Profitable Nanotech-Gesellschaften gibt es nicht gerade viele!!

Grüße Dirac